Purinergic signalling, ie, the role of nucleotides as extracellular signalling molecules, was
proposed in 1972. However, this concept was not well accepted until the early 1990's when …

This review is focused on the pathophysiology and therapeutic potential of purinergic
signalling. A wide range of diseases are considered, including those of the central nervous …

The concept of a purinergic signalling system, using purine nucleotides and nucleosides as
extracellular messengers, was first proposed over 30 years ago. After a brief historical …

Purine receptor subtypes are expressed with some selectivity on different types of cells in
the cardiovascular system and are possible targets for therapeutic strategies in …

Purinergic signalling, ie ATP as an extracellular signalling molecule and cotransmitter in
both peripheral and central neurons, is involved in the physiology of neurotransmission and …

Abstract P2Y receptors are G-protein-coupled receptors (GPCRs) for extracellular
nucleotides. There are eight mammalian P2Y receptor subtypes (P2Y 1, P2Y 2, P2Y 4, P2Y …

Membrane receptors that are activated by the purine nucleoside adenosine (adenosine
receptors) or by purine or pyrimidine nucleotides (P2Y and P2X receptors) transduce …

In the last decade, the field of purinergic pharmacology has continued to grow as the
complexity of the receptor families and the various enzymes involved in purine metabolism …

A brief account of the early history of extracellular signalling by ATP will be followed by a
summary of the current subclassification of receptors for purines and pyrimidines. On the …

Importance of the field: P2X channels are ionotropic purinergic receptors that are currently
under scrutiny as attractive targets for novel therapeutics in areas including chronic …